Person profile

Public information reviewed

Dennis M. McGrath

Board role

Director · CITIUS ONCOLOGY, INC. (NASDAQ: CTOR)

Board role

Director · Citius Pharmaceuticals, Inc. (NASDAQ: CTXR)

Board role

Director · DarioHealth Corp. (NASDAQ: DRIO)

Board role

Director · PAVmed Inc. (NASDAQ: PAVM)

CITIUS ONCOLOGY, INC. (NASDAQ: CTOR)

Director · Current mandate

Director · Executive
FollowSave PDF
More
Reports & analysis (Check report directory)Alpha Eval
Evidence records
16
Profile ownership
Not yet claimed
Record reviewed
May 16, 2026
View evidence

Structured intelligence coverage

Structured records are temporarily unavailable. The published profile and its source ledger remain accessible.

Identity checks do not refresh the age of governance evidence. Open a record for its source date and review state.

Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
44 current organizations shown on this profile
Board positions
44 supported by public sources, 0 supplied by the profile owner
Committee roles
4Roles supported by the sources cited on this profile
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Experienced CFO and President with extensive background in medical device companies and M&A transactions. Certified Public Accountant with 40+ years of experience in finance and executive leadership roles.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

Board appointments

Governance

Board appointments, committee responsibilities and disclosed relationships.

Committee appointments across companies · Temporarily unavailable

Structured records for this section are unavailable. This does not establish that no records exist. Published profile sources remain in Evidence & History.

Board and advisory record

Board service

Sources are shown with each role, education record, or credential.

Director

CITIUS ONCOLOGY, INC.

2024-01-01 · current

Confirmed by public sourceView source

Director

Citius Pharmaceuticals, Inc.

2023-01-01 · current

Confirmed by public sourceView source

Director

DarioHealth Corp.

2013-01-01 · current

Confirmed by public sourceView source

Director

PAVmed Inc.

Current · start date not disclosed

Confirmed by public sourceView source

Connections

Explore the roles, education and affiliations published in this record.

CITIUS ONCOLOGY, INC.

Open CITIUS ONCOLOGY, INC. profile →

Director at CITIUS ONCOLOGY, INC.

2024-01-01 → End not stated

current · source reported

Observed: 2026-09-26

CITIUS ONCOLOGY, I…CITIUS ONCOLOGY, INC.Citius Pharmaceuti…Citius Pharmaceuticals, Inc.DarioHealth Corp.DarioHealth Corp.PAVmed Inc.PAVmed Inc.Dennis M. McGrath

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec FilingPAVM DEF 14A executive officersSupports AI and ML experience, Cybersecurity experience, Executive company, Executive title, Other Company Role, Technology background.Open sourceSource 2 · Sec FilingLUCD DEF 14A executive officersSupports Executive company, Executive title.Open sourceSource 3 · Sec FilingDRIO 10-K executive officersSupports Executive company, Executive title.Open sourceSource 4 · Sec FilingPAVM DEF 14A director slateSupports AI and ML experience, Board role, Committee assignments, Cybersecurity experience, Technology background.Open sourceSource 5 · Sec FilingCTXR DEF 14A director slateSupports Board role, Committee assignments.Open sourceSource 6 · Sec FilingCTOR 10-K executive officersSupports Executive company, Executive title.Open sourceSource 7 · Sec FilingDRIO DEF 14A director slateSupports Board role, Committee assignments, Executive company, Executive title.Open sourceSource 8 · Sec FilingCTOR DEF 14A director slateSupports Board role, Committee assignments.Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:dennis-m-mcgrath
Record version
public-0

Published evidence records

16 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. PAVM DEF 14A executive officers

    sec filing · Source published: Apr 30, 2026 · Retrieved: May 16, 2026

    Supports 6 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Executive company: Executive at PAVmed, Inc. · Claim reviewed: May 16, 2026
    • Executive title: Executive title: President and Chief Financial Officer · Claim reviewed: May 16, 2026
    • Other Company Role: Dennis M. McGrath is also linked to Lucid Diagnostics Inc. as Chief Financial Officer. · Claim reviewed: May 16, 2026
    • Technology background: Technology background reported in filings · Claim reviewed: May 16, 2026

  2. LUCD DEF 14A executive officers

    sec filing · Source published: Apr 30, 2026 · Retrieved: May 16, 2026

    Supports 2 claims
    • Executive company: Executive at Lucid Diagnostics Inc. · Claim reviewed: May 16, 2026
    • Executive title: Executive title: Chief Financial Officer · Claim reviewed: May 16, 2026

  3. DRIO 10-K executive officers

    sec filing · Source published: Mar 19, 2026 · Retrieved: May 16, 2026

    Supports 2 claims
    • Executive company: Executive at DarioHealth Corp. · Claim reviewed: May 16, 2026
    • Executive title: Executive title: Director · Claim reviewed: May 16, 2026

  4. PAVM DEF 14A director slate

    sec filing · Source published: Feb 24, 2026 · Retrieved: May 16, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Board role: Board role: Director · Claim reviewed: May 16, 2026
    • Committee assignments: No committee assignment disclosed in the cited filing · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  5. CTXR DEF 14A director slate

    sec filing · Source published: Feb 24, 2026 · Retrieved: May 15, 2026

    Supports 2 claims
    • Board role: Board role: Director · Claim reviewed: May 16, 2026
    • Committee assignments: Committee assignments: Audit and Risk, Nominating/Governance · Claim reviewed: May 15, 2026

  6. Open source

    sec proxy · Source published: Feb 24, 2026 · Retrieved: Apr 25, 2026

    Supports 1 claim
    • Professional Role: Director at Citius Pharmaceuticals, Inc. · Claim reviewed: May 16, 2026

  7. Open source

    sec proxy · Source published: Feb 24, 2026 · Retrieved: Apr 25, 2026

    Supports 1 claim
    • Professional Role: Director at PAVmed Inc. · Claim reviewed: May 16, 2026

  8. CTOR 10-K executive officers

    sec filing · Source published: Dec 23, 2025 · Retrieved: May 16, 2026

    Supports 2 claims
    • Executive company: Executive at CITIUS ONCOLOGY, INC. · Claim reviewed: May 16, 2026
    • Executive title: Executive title: Director · Claim reviewed: May 16, 2026

  9. DRIO DEF 14A director slate

    sec filing · Source published: Dec 22, 2025 · Retrieved: May 15, 2026

    Supports 4 claims
    • Board role: Board role: Director · Claim reviewed: May 16, 2026
    • Committee assignments: Committee assignments: Audit, Compensation · Claim reviewed: May 15, 2026
    • Executive company: Executive at PAVmed, Inc. · Claim reviewed: May 16, 2026
    • Executive title: Executive title: Executive Vice President and Chief Financial Officer · Claim reviewed: May 15, 2026

  10. Open source

    sec proxy · Source published: Dec 22, 2025 · Retrieved: Apr 25, 2026

    Supports 1 claim
    • Professional Role: Director at DarioHealth Corp. · Claim reviewed: May 16, 2026

  11. CTOR DEF 14A director slate

    sec filing · Source published: Sep 26, 2025 · Retrieved: May 15, 2026

    Supports 2 claims
    • Board role: Board role: Director · Claim reviewed: May 16, 2026
    • Committee assignments: Committee assignments: Audit and Risk, Nominating/Governance · Claim reviewed: May 15, 2026

  12. Open source

    sec proxy · Source published: Sep 26, 2025 · Retrieved: Apr 28, 2026

    Supports 1 claim
    • Professional Role: Director at CITIUS ONCOLOGY, INC. · Claim reviewed: May 16, 2026

  13. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of CITIUS ONCOLOGY, INC. · Claim reviewed: May 16, 2026

  14. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Citius Pharmaceuticals, Inc. · Claim reviewed: May 16, 2026

  15. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of DarioHealth Corp. · Claim reviewed: May 16, 2026

  16. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of PAVmed Inc. · Claim reviewed: May 16, 2026

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · CorroboratedAI and ML experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Board membership · Source reportedServes on the board of CITIUS ONCOLOGY, INC.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board membership · Source reportedServes on the board of Citius Pharmaceuticals, Inc.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board membership · Source reportedServes on the board of DarioHealth Corp.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board membership · Source reportedServes on the board of PAVmed Inc.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board role · CorroboratedBoard role: DirectorSupported by 4 public records4 sources
Verification
Corroborated
Confidence
92%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Committee assignments · Source reportedNo committee assignment disclosed in the cited filing1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Committee assignments · CorroboratedCommittee assignments: Audit and Risk, Nominating/GovernanceSupported by 2 public records2 sources
Verification
Corroborated
Confidence
88%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Committee assignments · Source reportedCommittee assignments: Audit, Compensation1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Cybersecurity experience · CorroboratedCybersecurity experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive company · Source reportedExecutive at CITIUS ONCOLOGY, INC.1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive company · Source reportedExecutive at DarioHealth Corp.1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive company · Source reportedExecutive at Lucid Diagnostics Inc.1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive company · CorroboratedExecutive at PAVmed, Inc.Supported by 2 public records2 sources
Verification
Corroborated
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive title · Source reportedExecutive title: Chief Financial Officer1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive title · CorroboratedExecutive title: DirectorSupported by 2 public records2 sources
Verification
Corroborated
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive title · Source reportedExecutive title: Executive Vice President and Chief Financial Officer1 source
Verification
Source reported
Confidence
85%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Executive title · Source reportedExecutive title: President and Chief Financial Officer1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Other Company Role · Source reportedDennis M. McGrath is also linked to Lucid Diagnostics Inc. as Chief Financial Officer.1 source
Verification
Source reported
Confidence
70%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Technology background · Under reviewTechnology background: not identified in the cited filing1 source
Verification
Under review
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Technology background · Under reviewTechnology background reported in filings1 source
Verification
Under review
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

View all sources16 records
  1. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: AI and ML experience · Cybersecurity experience · Executive company · Executive title · Other Company Role · Technology background

  2. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: Executive company · Executive title

  3. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: Executive company · Executive title

  4. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: AI and ML experience · Board role · Committee assignments · Cybersecurity experience · Technology background

  5. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

    Supports: Board role · Committee assignments

  6. https://www.sec.gov/Archives/edgar/data/1506251/000121390026019566/ea0277108-def14a_citius.htm

    Sec Proxy · Tier not stated · Reviewed Apr 25, 2026

    Supports: Director at Citius Pharmaceuticals, Inc. (NASDAQ: CTXR)

  7. https://www.sec.gov/Archives/edgar/data/1624326/000149315226007884/formdef14a.htm

    Sec Proxy · Tier not stated · Reviewed Apr 25, 2026

    Supports: Director at PAVmed Inc. (NASDAQ: PAVM)

  8. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: Executive company · Executive title

  9. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

    Supports: Board role · Committee assignments · Executive company · Executive title

  10. https://www.sec.gov/Archives/edgar/data/1533998/000110465925123724/tm2533158-3_def14a.htm

    Sec Proxy · Tier not stated · Reviewed Apr 25, 2026

    Supports: Director at DarioHealth Corp. (NASDAQ: DRIO)

  11. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

    Supports: Board role · Committee assignments

  12. https://www.sec.gov/Archives/edgar/data/1851484/000121390025092369/ea0257805-def14a_citius.htm

    Sec Proxy · Tier not stated · Reviewed Apr 28, 2026

    Supports: Director at CITIUS ONCOLOGY, INC. (NASDAQ: CTOR)

  13. https://www.sec.gov/Archives/edgar/data/1851484/000121390025092369/ea0257805-def14a_citius.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership

  14. https://www.sec.gov/Archives/edgar/data/1506251/000121390026019566/ea0277108-def14a_citius.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership

  15. https://www.sec.gov/Archives/edgar/data/1533998/000110465925123724/tm2533158-3_def14a.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership

  16. https://www.sec.gov/Archives/edgar/data/1624326/000149315226007884/formdef14a.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership